Objectives
To analyze the expression and potential role of interleukin (IL) 21 in the pathogenesis of Vogt-Koyanagi-Harada (VKH) disease.
Methods
Blood samples were obtained from patients with VKH disease and from healthy control subjects. Serum IL-21 level and IL-21 messenger RNA (mRNA) expression by peripheral blood mononuclear cells (PBMCs) were determined by enzyme-linked immunosorbent assay and by reverse transcriptase–polymerase chain reaction, respectively. Interleukin 17 and interferon γ levels in the supernatants of PBMCs and CD4+ T cells cultured with anti-CD3 and anti-CD28 antibodies in the presence or absence of recombinant IL-21 were detected by enzyme-linked immunosorbent assay.
Results
The results showed a significantly increased serum IL-21 level, as well as higher IL-21 mRNA expression by PBMCs, in patients having chronic or recurrent active VKH disease compared with patients having inactive VKH disease and with controls. In vitro experiments showed that recombinant IL-21 significantly increased IL-17 production by PBMCs and by CD4+ T cells from patients and from controls. However, recombinant IL-21 did not affect interferon γ expression by PBMCs or by CD4+ T cells.
Conclusion
Interleukin 21 may be involved in the pathogenesis of chronic or recurrent VKH disease, possibly by promoting IL-17 secretion.
Clinical Relevance
Findings from the present study suggest that IL-21 may be a potential target in the development of therapy for VKH disease.
Vogt-Koyanagi-Harada (VKH) disease is a systemic autoimmune disorder involving the eye, meninges, ear, skin, and hair. Bilateral granulomatous panuveitis is the hallmark of VKH disease and frequently results in severely decreased vision or even blindness if not treated appropriately.1 The pathogenesis of VKH disease is not completely understood, although extensive investigations have been performed. Results of previous studies2,3 suggested that CD4+ helper T cells, subtype 1 (TH1s) are involved in the development of VKH disease. Recent evidence from our group indicated that the CD4+ TH17 and interleukin (IL) 23 pathway may also have an active role in this disease.4
Findings from recent studies5-9 revealed that IL-21 promotes the differentiation of TH17s in autoimmune diseases. Interleukin 21, a member of the IL-2 family of cytokines, exerts pleiotropic effects on the immune system10 and has a role in the pathogenesis of several autoimmune diseases, including inflammatory bowel diseases,5,6,11 rheumatoid arthritis,12,13 psoriasis,14 multiple sclerosis,15 systemic sclerosis,16 systemic lupus erythematosus,17,18 and type 1 diabetes mellitus in nonobese diabetic mice.9 Distinct aspects of IL-21 are that it is mainly derived from activated CD4+ T cells and that it regulates the development of CD4+ T cells.10 Earlier studies11,13 showed that IL-21 was associated with a predominant TH1 response and with increased interferon (IFN) γ production. The present study was designed to examine whether IL-21 is involved in VKH disease and how it affects IL-17 and IFN-γ expression.
Thirty patients with VKH disease (14 men and 16 women [mean age, 33.4 years]) and 21 healthy control subjects (10 men and 11 women [mean age, 32.5 years]) were included in the study. The diagnosis of VKH disease was made according to the revised diagnostic criteria.19 Among the patients with VKH disease, 15 had complete VKH disease, 13 had incomplete VKH disease, and 2 had probable VKH disease with typical bilateral sunset glow fundus and granulomatous anterior uveitis. Sixteen patients had chronic or recurrent active bilateral intraocular inflammation evidenced by mutton-fat keratic precipitates, cells in the anterior chamber, and aqueous flare in association with sunset glow fundus. Patients with active disease had received no immunosuppressive drugs for at least 1 week before study evaluation and blood drawing. Fourteen patients having inactive VKH disease with typical bilateral sunset glow fundus but without intraocular inflammation for at least 3 months after treatment formed a separate study group. Twelve patients with inactive disease had received no immunosuppressive drugs for at least 3 months, while 2 patients with inactive disease had received a small dosage of oral prednisone (5 mg every other day) for 1 month before blood drawing. This study was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. All procedures followed the tenets of the Declaration of Helsinki, and informed consent was obtained from all patients with VKH disease and from controls.
Blood samples were collected by venipuncture and were processed after clotting for 30 minutes at room temperature. Serum specimens were obtained by centrifugation at 3000 g for 10 minutes and stored at −70°C until analysis.
Cell isolation and culture
Anticoagulated blood samples were obtained using vacuum tubes containing EDTA. Peripheral blood mononuclear cells (PBMCs) were prepared by Ficoll-Hypaque density-gradient centrifugation. CD4+ T cells were purified by magnetic-activated cell sorting using a human CD4+ T-cell isolation kit (Miltenyi Biotec, Palo Alto, California). The PBMCs and CD4+ T cells were stimulated with anti-CD3 (OKT3, 0.5 μg/mL) and anti-CD28 antibodies (15E8, 0.1 μg/mL) (Miltenyi Biotec) in the presence or absence of recombinant (r) IL-21 (30 ng/mL) (PeproTech, Rocky Hill, New Jersey).
Rna preparation and reverse transcriptase–polymerase chain reaction
Total RNA was extracted from freshly isolated PBMCs using a commercially available kit (RNeasy Plus Mini kit; Qiagen, Valencia, California) according to the manufacturer's instructions. The following primers were used for reverse transcriptase–polymerase chain reaction (RT-PCR): IL-21 forward, 5′-GGCCCAACTAAAGTCAGCAAATA-3′, and IL-21 reverse, 5′-GGGCATGTTAGTCTGTGTTTCTG-3′ (38 cycles at 62°C); and β-actin forward, 5′-GGATGCAGAAGGAGATCACTG-3′, and β-actin reverse, 5′-CGATCCACACGGAGTACTTG-3′ (30 cycles at 60°C). The ratio of IL-21 RT-PCR product to β-actin product was analyzed to quantitate the level of IL-21 messenger RNA (mRNA) expression. The identity of IL-21 and β-actin RT-PCR products was verified by sequencing using a commercially available system (Applied Biosystems model 3730 DNA sequencing system; Invitrogen Biotechnology Co, Shanghai, China).
Enzyme-linked immunosorbent assay for cytokines
The concentration of serum IL-21 in patients and controls was assayed using a human IL-21 enzyme-linked immunosorbent assay kit (DuoSet; eBioscience, San Diego, California) with a detection limit of 31 pg/mL. The concentrations of IL-17 and IFN-γ in cell culture supernatants were measured using enzyme-linked immunosorbent assay development kits (DuoSet; R&D Systems, Minneapolis, Minnesota) with a detection limit of 15 pg/mL.
One-way analysis of variance, paired-sample t test, Kruskal-Wallis test, and Mann-Whitney test were performed using commercially available statistical software (SPSS 12.0; SPSS Inc, Chicago, Illinois). Data are expressed as the mean (SD). P < .05 was considered statistically significant, while P < .05 divided by 3 (P < .02 [modified by Bonferroni correction]) was accepted in multiple comparisons.
Our results suggest that IL-21 is markedly upregulated during active uveitis episodes. Furthermore, rIL-21 may have a role in chronic or recurrent VKH disease by promoting IL-17 production.
Il-21 concentration in serum samples of patients with vkh disease and controls
Interleukin 21 was detected in serum samples from patients with VKH disease and from controls (Figure 1). The mean level of IL-21 in patients with chronic or recurrent active VKH disease was significantly higher (212.2 [67.9] pg/mL) than that in patients with inactive VKH disease (90.1 [23.9] pg/mL) and in controls (90.8 [27.0] pg/mL) (P < .01 for both). There was no significant difference in serum IL-21 level between patients with inactive VKH disease and controls.
EXPRESSION OF IL-21 mRNA BY PBMCS FROM PATIENTS WITH VKH DISEASE AND FROM CONTROLS
DNA sequencing and BLAST analysis (http://www.ncbi.nlm.nih.gov/Education/BLASTinfo/information3.html) showed that RT-PCR products were identified as 100% homologous with the known IL-21 mRNA sequence. The IL-21 mRNA band intensity was normalized compared with the β-actin mRNA band. The mean intensity ratio of IL-21 RT-PCR product to β-actin product in patients with chronic or recurrent active VKH disease (0.68 [0.11]) was markedly higher than that in patients with inactive VKH disease (0.52 [0.08]) and in controls (0.52 [0.03]) (P < .01 for both) (Figure 2). No ratio difference was found between patients with inactive VKH disease and controls.
EFFECT OF rIL-21 ON IL-17 PRODUCTION
Interleukin 17 production was significantly increased by stimulation with anti-CD3 and anti-CD28 antibodies in patients having chronic or recurrent active VKH disease compared with patients having inactive VKH disease and with controls (P < .01 for both). Significant augmentation of IL-17 production by PBMCs on exposure to rIL-21 was found in all 3 study groups (P < .05 for all) (Figure 3A). Increased percentages of IL-17 production by PBMCs on stimulation by rIL-21 were 19.1% in patients with chronic or recurrent active VKH disease, 17.0% in patients with inactive VKH disease, and 25.5% in controls. Using analysis of variance, there was no difference among the 3 study groups in the magnitude of rIL-21 effect on IL-17 production by PBMCs. A further study was performed to examine the effect of rIL-21 on IL-17 production by activated CD4+ T cells. Consistent with the PBMC results, the IL-17 level in the supernatants of cultured CD4+ T cells was significantly higher in patients with chronic or recurrent active VKH disease than in patients with inactive VKH disease or in controls (P < .01 for both) (Figure 3B). Recombinant IL-21 induced activated CD4+ T cells to secrete a much higher amount of IL-17 (P < .05 for all). However, similar to the PBMC results, no difference was found in the magnitude of rIL-21 effect on IL-17 production by CD4+ T cells among the 3 study groups using the Kruskal-Wallis test.
EFFECT OF rIL-21 ON IFN-γ PRODUCTION
We also detected IFN-γ in the supernatants of PBMCs and CD4+ T cells following stimulation with anti-CD3 and anti-CD28 antibodies (Figure 4). Interferon γ production by PBMCs and by CD4+ T cells was significantly higher in patients with chronic or recurrent active VKH disease than in patients with inactive VKH disease and in controls (P < .02 for all). However, rIL-21 did not affect IFN-γ production by PBMCs and by CD4+ T cells in patients with VKH disease or in controls.
Vogt-Koyanagi-Harada disease is believed to be mediated by TH1s and by TH17s.2-4 The present study investigated the expression of IL-21 in patients with VKH disease and its effect on the expression of IL-17 and IFN-γ. The results revealed significantly higher expression of IL-21 at the protein and mRNA levels in patients having chronic or recurrent active VKH disease compared with patients having inactive VKH disease and with controls. Recombinant IL-21 significantly stimulated IL-17 secretion by PBMCs and by CD4+ T cells from patients and from controls. However, it did not affect IFN-γ production by PBMCs or by CD4+ T cells.
As a multifunctional cytokine produced mostly by activated natural killer T cells and by CD4+ T cells, IL-21 is involved in various immune inflammatory diseases.10 To test whether IL-21 has a role in the development of VKH disease, we evaluated the expression of IL-21 at the protein and mRNA levels in patients having VKH disease with or without active uveitis and in controls. Increased expression of IL-21 was observed in serum samples of patients with chronic or recurrent active VKH disease. Consistent with serum specimen results, significantly higher IL-21 mRNA expression was observed in patients with chronic or recurrent active VKH disease. These results indicated that increased expression of peripheral circulating IL-21 correlated with VKH disease activity. Our findings are in line with evidence showing increased IL-21 expression in serum or PBMCs in animal models20 and in patients with systemic lupus erythematosus,17 primary Sjögren syndrome,21 and psoriasis.14 Interleukin 21 has also been reported to be overexpressed in affected tissues of patients with Crohn disease11,22 and with psoriasis.14 These data collectively reveal that IL-21 is associated with the activity of autoimmune diseases. It is notable that serum IL-21 reference levels from difference laboratories range from 16.5 pg/mL23 to 1051 pg/mL.21 This wide range may be attributed to different techniques used in the experiments or to different populations tested.
In light of the association between increased serum IL-21 and VKH disease activity, we extended our research to the role of IL-21 in this disease. Because TH17s have a role in the pathogenesis of VKH disease,4 we first analyzed the effect of rIL-21 on the production of IL-17. Consistent with a previous study,4 increased IL-17 was observed in the active stage of VKH disease, suggesting a correlation between upregulated IL-21 and IL-17 production. The results herein showed that rIL-21 markedly stimulated IL-17 production by PBMCs from patients with VKH disease and from controls. Because CD4+ T cells have a critical role in the development of VKH disease, we further tested the effect of IL-21 on IL-17 production by these cells. Similar results were observed with PBMCs and with isolated CD4+ T cells. These findings validate the promotional effect of rIL-21 on IL-17 production, as reported in various autoimmune diseases.5-9,14 Unexpectedly, we failed to find any difference in the magnitude of the effect of rIL-21 on IL-17 production among the 3 study groups. These results seem to suggest that increased IL-17 production by PBMCs or by CD4+ T cells may be due to upregulated IL-21 rather than by higher sensitivity of these cells to this cytokine in this disease. In contrast, other studies24,25 failed to observe an effect of IL-21 on TH17s. This discrepancy may be explained by different experimental approaches and varied disease backgrounds in the studies.
Because TH1s are actively involved in VKH disease,2,3 our study further examined whether rIL-21 affected the expression of IFN-γ, a typical cytokine of TH1s, in patients with VKH disease. The results showed significantly increased IFN-γ production by PBMCs and CD4+ T cells activated by anti-CD3 and anti-CD28 antibodies in patients having chronic or recurrent active VKH disease compared with patients having inactive VKH disease and with controls. This finding was consistent with previously reported results.4 However, we found no effect of rIL-21 on IFN-γ production by PBMCs or by CD4+ T cells from patients with VKH disease and from controls. This result was generally consistent with findings in healthy individuals.6,13 However, IL-21 has been shown to potently promote IFN-γ expression by activated T cells from patients with rheumatoid arthritis13 and with inflammatory bowel diseases.6 Contrary to these results, other investigators have suggested a suppressive effect of IL-21 on IFN-γ production by TH1s in their developmental stage26 or by T cells in 2 animal models of rheumatoid arthritis treated with IL-21 receptor Fc fusion protein to block IL-21.12 These discrepant findings are not yet completely understood. The involvement of different mechanisms in different diseases may be an explanation. The use of varied techniques and conditions in the experiments may be another possibility.
In conclusion, the present study revealed an association of upregulated IL-21 with increased IL-17 in patients having chronic or recurrent VKH disease with active intraocular inflammation. Recombinant IL-21 effectively and equally stimulated IL-17 production by PBMCs and by CD4+ T cells from patients with VKH disease and from controls. However, rIL-21 did not affect IFN-γ expression by PBMCs or by CD4+ T cells. These results suggest that IL-21 may be involved in the pathogenesis of chronic or recurrent VKH disease, possibly by promoting IL-17 secretion. Recent evidence indicates that IL-21 is critical for differentiation and function of follicular THs and that these cells are also involved in the development of autoimmune diseases.27 Future studies should investigate whether IL-21 may have a role in VKH disease through modulation of follicular THs. In addition, IL-21 has been shown to affect CD8+ T cells, natural killer T cells, and B cells, which are all involved in autoimmune diseases.10 More studies are needed to clarify the effect of IL-21 on these cells and their possible role in VKH disease.
Correspondence: Peizeng Yang, MD, PhD, The First Affiliated Hospital of Chongqing Medical University, Youyi Rd 1, Chongqing 400016, China (peizengycmu@126.com).
Submitted for Publication: December 31, 2009; final revision received April 2, 2010; accepted May 4, 2010.
Financial Disclosure: None reported.
Funding/Support: This work was supported by grant 30630064 from the Key Project of National Science Foundation, by grant 2007BAI18B10 from the National Supporting Project of China, by grant 30973242 from the National Nature Science Foundation Project, by grant 2008115 from the Key Project of Health Bureau of Chongqing, by grant 2008-1-15 from the Key Project of Medical Science and Technology of Chongqing, by grant Chongqing Science and Technology Commission (CSTC) 2009BA5037 from the Key Project of Nature Science Foundation of Chongqing, by Project of Chongqing, by grant CSTC 2008CA5003 from the Project of Chongqing Key Laboratory of Ophthalmology, and by Program for the Trainning of a Hundred Outstanding Science and Technology Leaders of Chongqing Municipality.
2.Li
BYang
PZhou
H
et al. Upregulation of T-bet expression in peripheral blood mononuclear cells during Vogt-Koyanagi-Harada disease.
Br J Ophthalmol 2005;89
(11)
1410- 1412
PubMedGoogle ScholarCrossref 3.Sugita
STakase
HTaguchi
C
et al. Ocular infiltrating CD4
+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens.
Invest Ophthalmol Vis Sci 2006;47
(6)
2547- 2554
PubMedGoogle ScholarCrossref 4.Chi
WYang
PLi
B
et al. IL-23 promotes CD4
+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease.
J Allergy Clin Immunol 2007;119
(5)
1218- 1224
PubMedGoogle ScholarCrossref 5.Fina
DSarra
MFantini
MC
et al. Regulation of gut inflammation and Th17 cell response by interleukin-21.
Gastroenterology 2008;134
(4)
1038- 1048
PubMedGoogle ScholarCrossref 6.Liu
ZYang
LCui
Y
et al. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease.
Inflamm Bowel Dis 2009;15
(8)
1133- 1144
PubMedGoogle ScholarCrossref 7.Korn
TBettelli
EGao
W
et al. IL-21 initiates an alternative pathway to induce proinflammatory T
(H)17 cells.
Nature 2007;448
(7152)
484- 487
PubMedGoogle ScholarCrossref 8.Nurieva
RYang
XOMartinez
G
et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells.
Nature 2007;448
(7152)
480- 483
PubMedGoogle ScholarCrossref 9.Spolski
RKashyap
MRobinson
CYu
ZLeonard
WJ IL-21 signaling is critical for the development of type I diabetes in the NOD mouse.
Proc Natl Acad Sci U S A 2008;105
(37)
14028- 14033
PubMedGoogle ScholarCrossref 10.Spolski
RLeonard
WJ Interleukin-21: basic biology and implications for cancer and autoimmunity.
Annu Rev Immunol 2008;2657- 79
PubMedGoogle ScholarCrossref 11.Monteleone
GMonteleone
IFina
D
et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-γ production in Crohn's disease.
Gastroenterology 2005;128
(3)
687- 694
PubMedGoogle ScholarCrossref 12.Young
DAHegen
MMa
HL
et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.
Arthritis Rheum 2007;56
(4)
1152- 1163
PubMedGoogle ScholarCrossref 13.Li
JShen
WKong
KLiu
Z Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis.
Scand J Immunol 2006;64
(5)
515- 522
PubMedGoogle ScholarCrossref 14.Caruso
RBotti
ESarra
M
et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis.
Nat Med 2009;15
(9)
1013- 1015
PubMedGoogle ScholarCrossref 15.Jones
JLPhuah
CLCox
AL
et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
J Clin Invest 2009;119
(7)
2052- 2061
PubMedGoogle Scholar 16.Distler
JHJüngel
AKowal-Bielecka
O
et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis.
Arthritis Rheum 2005;52
(3)
856- 864
PubMedGoogle ScholarCrossref 17.Wang
XFYuan
SLJiang
L
et al. Changes of serum BAFF and IL-21 levels in patients with systemic lupus erythematosus and their clinical significance [in Chinese].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2007;23
(11)
1041- 1042
PubMedGoogle Scholar 18.Herber
DBrown
TPLiang
SYoung
DACollins
MDunussi-Joannopoulos
K IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression.
J Immunol 2007;178
(6)
3822- 3830
PubMedGoogle ScholarCrossref 19.Read
RWHolland
GNRao
NA
et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.
Am J Ophthalmol 2001;131
(5)
647- 652
PubMedGoogle ScholarCrossref 20.Ozaki
KSpolski
REttinger
R
et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6.
J Immunol 2004;173
(9)
5361- 5371
PubMedGoogle ScholarCrossref 21.Yuan
SLJiang
LZhang
XLLi
SFDuan
HMWang
XF Serum IL-21 level in patients with primary Sjogren's syndrome and clinical significance of IL-21 [in Chinese.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2007;23
(2)
124- 126
PubMedGoogle Scholar 22.Caprioli
FSarra
MCaruso
R
et al. Autocrine regulation of IL-21 production in human T lymphocytes.
J Immunol 2008;180
(3)
1800- 1807
PubMedGoogle ScholarCrossref 23.Chatterjee
RBatra
JGhosh
B A common exonic variant of interleukin21 confers susceptibility to atopic asthma.
Int Arch Allergy Immunol 2009;148
(2)
137- 146
PubMedGoogle ScholarCrossref 24.Bubier
JASproule
TJForeman
O
et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice.
Proc Natl Acad Sci U S A 2009;106
(5)
1518- 1523
PubMedGoogle ScholarCrossref 25.Sonderegger
IKisielow
JMeier
RKing
CKopf
M IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo.
Eur J Immunol 2008;38
(7)
1833- 1838
PubMedGoogle ScholarCrossref 26.Wurster
ALRodgers
VLSatoskar
AR
et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon γ-producing Th1 cells.
J Exp Med 2002;196
(7)
969- 977
PubMedGoogle ScholarCrossref 27.King
CTangye
SGMackay
CR T follicular helper (TFH) cells in normal and dysregulated immune responses.
Annu Rev Immunol 2008;26741- 766
PubMedGoogle ScholarCrossref